Effect of ORM-12741 on Receptor Occupancy Studied by Positron Emission Tomography; an Open, Single Dose, Dose Ranging Study in Healthy Males.
Phase of Trial: Phase I
Latest Information Update: 18 Feb 2013
At a glance
- Drugs ORM 12741 (Primary)
- Indications Depressive disorders; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Orion
- 09 Dec 2009 Actual patient number (26) added as reported by ClinicalTrials.gov.
- 09 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Dec 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.